CPT code 87475 denotes a molecular diagnostic test using a direct nucleic acid probe to detect Borrelia burgdorferi, the bacterium responsible for Lyme disease. As a targeted infectious disease assay, this code captures a laboratory method that can provide direct evidence of bacterial genetic material and inform clinical decision-making for suspected Lyme disease. Nationally, accurate coding for molecular diagnostics affects laboratory billing, public health surveillance, and payer coverage determinations for infectious disease testing.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the test, typical sites of service where it is performed, and the role of this assay in the diagnostic pathway for Lyme disease. The publication presents national benchmarks where available, summarizes relevant payment and coverage considerations, and highlights operational implications for laboratories and clinicians ordering molecular infectious disease testing.

Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, related codes, and detailed payer-specific reimbursement rates is noted within the full publication. The focus here is on clarifying the clinical purpose and billing identity of CPT code 87475 for stakeholders across clinical, laboratory, and payer settings.